A Phase 3 interventional study of Ocrelizumab and Placebo in Multiple Sclerosis, Primary Progressive, sponsored by Hoffmann-La Roche. Completed at 184 sites in 29 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2024-01-10.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing ocrelizumab in Multiple Sclerosis, Chronic Progressive — 2 open to participants now, 6 under way, 4 of them phase 3. ocrelizumab · Multiple Sclerosis, Chronic Progressive.
Among the 10 studies testing ocrelizumab in Multiple Sclerosis, Chronic Progressive, this one is the 4th largest by enrollment, is the only one that started in 2011, is one of 7 in phase 3, and was the 1st registered.
245 studies on the registry are indexed under Multiple Sclerosis, Chronic Progressive; 54 are open to participants now.
Browse Multiple Sclerosis, Chronic Progressive studies →2 of the 10 studies testing ocrelizumab in Multiple Sclerosis, Chronic Progressive are open now, in 3 countries. Recruiting first, the newest first:
Genentech, Inc. · Sites in United States, Puerto Rico
Ages 18–65
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–60 · Healthy volunteers
By country, each count listing its studies:
ocrelizumab: first FDA approval 2017 (OCREVUS), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 39 Multiple Sclerosis, Chronic Progressive studies recruiting now, 7 (18%) set no upper age limit and 26 (67%) stop at 75 or younger; none take children under 18; 6 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 1 · Phase 3 8 · Phase 4 2
First in 2011; this study’s year is marked. 1 started in 2011.
This study's enrollment of 735 is above the median of 54 across 190 interventional studies indexed under Multiple Sclerosis, Chronic Progressive.
Median enrollment 184 across the 10 interventional studies. Of the 4 that completed or were terminated, 4 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 10 have an industry lead sponsor. The 4 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
12 studies in Multiple Sclerosis, Chronic Progressive by Hoffmann-La Roche: 2 open now, 8 under way, 4 of them phase 3. Of 4 finished, 4 (100%) have results posted.
Among the 12 studies in Multiple Sclerosis, Chronic Progressive by Hoffmann-La Roche, this one is the 5th largest by enrollment, is the only one that started in 2011, is one of 7 in phase 3, and was the 2nd registered.
Hoffmann-La Roche’s Multiple Sclerosis, Chronic Progressive studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing ocrelizumab in Multiple Sclerosis, Chronic Progressive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 12 in Multiple Sclerosis, Chronic Progressive:
This tab as a report to print or save as PDF → With an account.
This randomized, parallel group, double-blind, placebo controlled study will evaluate the efficacy and safety of ocrelizumab in participants with primary progressive multiple sclerosis. Eligible participants will be randomized 2 : 1 to receive either ocrelizumab or placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with primary progressive multiple sclerosis (PPMS) received placebo matched to ocrelizumab at a schedule interval of 24 weeks up to at least 120 weeks.
Drug: Ocrelizumab · Other: Placebo
Participants with PPMS received ocrelizumab as two IV infusions of 300 mg separated by 14 days at a scheduled interval of every 24 weeks up to at least 120 weeks.
Drug: Ocrelizumab
Two IV infusions of 300 mg in each treatment cycle of double blind treatment period; two IV infusions of ocrelizumab 300 mg for Cycle 1 and single IV infusion of ocrelizumab 600 mg for subsequent cycles in OLE phase.
Two IV infusions of placebo matched to ocrelizumab in each treatment cycle of double blind treatment period.
Time to Onset of Clinical Disability Progression (CDP) Sustained for at Least 12 Weeks During the Double-Blind Treatment Period
The time to onset of CDP was defined as time from baseline to first disability progression, which is confirmed at next regularly scheduled visit \>=12 weeks (\>=84 days) after initial disability progression. Baseline for time to onset of CDP is the date of randomization, independent of the first day of dosing. Disability progression is defined as an increase of \>= 1.0 point from baseline expanded disability status scale (EDSS) score, if baseline EDSS value is \<=5.5 points (inclusive), or an increase of \>=0.5 points, if baseline EDSS is \>5.5 points. The total EDSS score ranges from 0 (normal) to 10 (death due to multiple sclerosis). The randomized participants who did not receive any treatment were censored at days 0 in each Arm.
Time frame: Maximal follow up: 216 weeks for Placebo arm and 217 weeks for Ocrelizumab arm
Time to Onset of Clinical Disability Progression (CDP) Sustained for at Least 24 Weeks During the Double-Blind Treatment Period
The time to onset of CDP was defined as time from baseline to first disability progression, which is confirmed at next regularly scheduled visit \>=12 weeks (\>=84 days) after initial disability progression. Baseline for time to onset of CDP is the date of randomization, independent of the first day of dosing. Disability progression is defined as an increase of \>= 1.0 point from baseline expanded disability status scale (EDSS) score, if baseline EDSS value is \<=5.5 points (inclusive), or an increase of \>=0.5 points, if baseline EDSS is \>5.5 points. The total EDSS score ranges from 0 (normal) to 10 (death due to multiple sclerosis). The randomized participants who did not receive any treatment were censored at days 0 in each Arm.
Time frame: Maximal follow up: 216 weeks for Placebo arm and 217 weeks for Ocrelizumab arm
Percent Change From Baseline in Timed 25-Foot Walk (T25-FW) at Week 120
Time frame: Baseline, Week 120
Percent Change From Baseline in Total Volume of T2 Lesions at Week 120
Time frame: From Baseline to Week 120
Percent Change in Total Brain Volume From Week 24 to Week 120
Time frame: From Week 24 to Week 120
Change in From Baseline Physical Component Summary Score (PCS) SF- 36 Health Survey (SF-36) at Week 120
The SF-36v2 is a 36-item, self- reported, generic measure of quality of life that has been widely used in multiple disease areas. It is composed of 8 health domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The PCS score was derived based on the SF-36 V2 User's Manual. Scoring for PCS involves (a) recoding item response values, (b) summing recoded response values for all items in a given scale to obtain the scale raw score, (c) transforming scale raw score to a 0-100 score. The PCS score was computed by (a) multiplying each health domain z score by a scale-specific physical factor score coefficient, (b) summing the resulting products, (c) converting the product total to T score. The total score ranges from 0-100, higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.
Time frame: From Baseline to Week 120
Number of Participants With at Least One Adverse Event (AE)
AEs included infusion related reactions (IRRs) and serious multiple sclerosis (MS) relapses, but excluded non-serious MS relapses.
Time frame: From baseline to 9 years
| Milestone | Placebo | Ocrelizumab 600 mg |
|---|---|---|
| Started | 244 | 488 |
| Completed | 89 | 218 |
| Not completed | 155 | 270 |
| Withdrew: Adverse event | 22 | 40 |
| Withdrew: Death | 6 | 20 |
| Withdrew: Lack of efficacy | 32 | 33 |
| Withdrew: Lost to follow-up | 4 | 15 |
| Withdrew: Non-compliance | 2 | 2 |
| Withdrew: Non-compliance with study drug | 2 | 2 |
| Withdrew: Other | 18 | 47 |
| Withdrew: Physician decision | 10 | 25 |
| Withdrew: Protocol violation | 1 | 2 |
| Withdrew: Study terminated by sponsor | 0 | 1 |
| Withdrew: Withdrawal by subject | 57 | 82 |
| Withdrew: Pregnancy | 1 | 1 |
The time to onset of CDP was defined as time from baseline to first disability progression, which is confirmed at next regularly scheduled visit \>=12 weeks (\>=84 days) after initial disability progression. Baseline for time to onset of CDP is the date of randomization, independent of the first day of dosing. Disability progression is defined as an increase of \>= 1.0 point from baseline expanded disability status scale (EDSS) score, if baseline EDSS value is \<=5.5 points (inclusive), or an increase of \>=0.5 points, if baseline EDSS is \>5.5 points. The total EDSS score ranges from 0 (normal) to 10 (death due to multiple sclerosis). The randomized participants who did not receive any treatment were censored at days 0 in each Arm.
| weeks | Placebo | Ocrelizumab 600 mg |
|---|---|---|
| Time to Onset of Clinical Disability Progression (CDP) Sustained for at Least 12 Weeks During the Double-Blind Treatment Period | NA (0 to NA) | NA (0 to NA) |
The time to onset of CDP was defined as time from baseline to first disability progression, which is confirmed at next regularly scheduled visit \>=12 weeks (\>=84 days) after initial disability progression. Baseline for time to onset of CDP is the date of randomization, independent of the first day of dosing. Disability progression is defined as an increase of \>= 1.0 point from baseline expanded disability status scale (EDSS) score, if baseline EDSS value is \<=5.5 points (inclusive), or an increase of \>=0.5 points, if baseline EDSS is \>5.5 points. The total EDSS score ranges from 0 (normal) to 10 (death due to multiple sclerosis). The randomized participants who did not receive any treatment were censored at days 0 in each Arm.
| weeks | Placebo | Ocrelizumab 600 mg |
|---|---|---|
| Time to Onset of Clinical Disability Progression (CDP) Sustained for at Least 24 Weeks During the Double-Blind Treatment Period | NA (0 to NA) | NA (0 to NA) |
| percent change | Placebo | Ocrelizumab 600 mg |
|---|---|---|
| Percent Change From Baseline in Timed 25-Foot Walk (T25-FW) at Week 120 | 55.097 (39.855 to 71.999) | 38.933 (29.222 to 49.374) |
| percent change | Placebo | Ocrelizumab 600 mg |
|---|---|---|
| Percent Change From Baseline in Total Volume of T2 Lesions at Week 120 | 7.426 (4.967 to 9.942) | -3.366 (-4.987 to -1.718) |
| percent change | Placebo | Ocrelizumab 600 mg |
|---|---|---|
| Percent Change in Total Brain Volume From Week 24 to Week 120 | -1.093 (-1.236 to -0.951) | -0.902 (-1.004 to -0.799) |
The SF-36v2 is a 36-item, self- reported, generic measure of quality of life that has been widely used in multiple disease areas. It is composed of 8 health domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The PCS score was derived based on the SF-36 V2 User's Manual. Scoring for PCS involves (a) recoding item response values, (b) summing recoded response values for all items in a given scale to obtain the scale raw score, (c) transforming scale raw score to a 0-100 score. The PCS score was computed by (a) multiplying each health domain z score by a scale-specific physical factor score coefficient, (b) summing the resulting products, (c) converting the product total to T score. The total score ranges from 0-100, higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.
| units on a scale | Placebo | Ocrelizumab 600 mg |
|---|---|---|
| Change in From Baseline Physical Component Summary Score (PCS) SF- 36 Health Survey (SF-36) at Week 120 | -1.108 (-2.394 to 0.177) | -0.731 (-1.655 to 0.193) |
AEs included infusion related reactions (IRRs) and serious multiple sclerosis (MS) relapses, but excluded non-serious MS relapses.
| Participants | Placebo | Ocrelizumab 600 mg | Placebo (Open Label Extension) | Ocrelizumab (Open Label Extension) |
|---|---|---|---|---|
| Serious Adverse Events | 53 | 99 | 59 | 167 |
| Adverse Events | 215 | 462 | 148 | 354 |
Collected over Baseline up to 615 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DB PLACEBO | 3/239 (1.3%) | 58/239 (24.3%) | 175/239 (73.2%) |
| DB OCRELIZUMAB | 3/486 (0.6%) | 104/486 (21.4%) | 400/486 (82.3%) |
| OLE PLACEBO | 4/158 (2.5%) | 59/158 (37.3%) | 134/158 (84.8%) |
| OLE OCRELIZUMAB | 19/369 (5.1%) | 167/369 (45.3%) | 318/369 (86.2%) |
| Event | DB PLACEBO | DB OCRELIZUMAB | OLE PLACEBO | OLE OCRELIZUMAB |
|---|---|---|---|---|
| COVID-19 PNEUMONIAInfections and infestations | 0/239 | 0/486 | 5/158 | 31/369 |
| URINARY TRACT INFECTIONInfections and infestations | 4/239 | 4/486 | 7/158 | 20/369 |
| PNEUMONIAInfections and infestations | 3/239 | 6/486 | 3/158 | 17/369 |
| COVID-19Infections and infestations | 0/239 | 0/486 | 2/158 | 12/369 |
| SEPSISInfections and infestations | 0/239 | 0/486 | 2/158 | 7/369 |
| UROSEPSISInfections and infestations | 2/239 | 2/486 | 2/158 | 7/369 |
| CELLULITISInfections and infestations | 0/239 | 3/486 | 2/158 | 5/369 |
| PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders | 0/239 | 0/486 | 1/158 | 5/369 |
| APPENDICITISInfections and infestations | 0/239 | 2/486 | 2/158 | 3/369 |
| INVASIVE DUCTAL BREAST CARCINOMANeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/239 | 2/486 | 2/158 | 0/369 |
| Event | DB PLACEBO | DB OCRELIZUMAB | OLE PLACEBO | OLE OCRELIZUMAB |
|---|---|---|---|---|
| INFUSION RELATED REACTIONInjury, poisoning and procedural complications | 61/239 | 194/486 | 40/158 | 56/369 |
| URINARY TRACT INFECTIONInfections and infestations | 57/239 | 103/486 | 44/158 | 127/369 |
| NASOPHARYNGITISInfections and infestations | 63/239 | 117/486 | 48/158 | 100/369 |
| COVID-19Infections and infestations | 0/239 | 0/486 | 21/158 | 76/369 |
| PNEUMONIAInfections and infestations | 0/239 | 0/486 | 21/158 | 76/369 |
| BACK PAINMusculoskeletal and connective tissue disorders | 38/239 | 59/486 | 23/158 | 54/369 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 30/239 | 56/486 | 23/158 | 57/369 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 14/239 | 60/486 | 14/158 | 56/369 |
| HEADACHENervous system disorders | 31/239 | 68/486 | 15/158 | 41/369 |
| DEPRESSIONPsychiatric disorders | 31/239 | 34/486 | 9/158 | 23/369 |
Analysis was performed on intent to treat (ITT) population which included all randomized participants in the study.
| Age, Categorical(Participants) | Placebo | Ocrelizumab 600 mg | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 244 | 488 | 732 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | Placebo | Ocrelizumab 600 mg | Total |
|---|---|---|---|
| Mean | 44.4 ± 8.3 | 44.7 ± 7.9 | 44.6 ± 8.0 |
| Sex: Female, Male(Participants) | Placebo | Ocrelizumab 600 mg | Total |
|---|---|---|---|
| Female | 124 | 237 | 361 |
| Male | 120 | 251 | 371 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Ocrelizumab 600 mg | Total |
|---|---|---|---|
| Hispanic or Latino | 14 | 32 | 46 |
| Not Hispanic or Latino | 206 | 385 | 591 |
| Unknown or Not Reported | 24 | 71 | 95 |
| Race (NIH/OMB)(Participants) | Placebo | Ocrelizumab 600 mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 5 | 5 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 5 | 9 | 14 |
| White | 235 | 454 | 689 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 4 | 20 | 24 |
Showing the first 100 of 184 sites across 29 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Ran from Mar 2011 to primary completion in Jul 2015, 52 months.
Results were first posted in Dec 2017, 2 years 5 months after primary completion. A results delay was requested in Oct 2016.
Of 20 phase 3 interventional studies under Multiple Sclerosis, Chronic Progressive, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 52 and three quarters within 83. This study's 52 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ocrelizumab
Multiple Sclerosis, Chronic Progressive →